Recombinant Human Interleukin-2/IL-2
Product name: | Recombinant Human Interleukin-2/IL-2 |
Source: | Human Cells |
Purity: | Greater than 95% as determined by reducing SDS-PAGE. |
Buffer Formulation: | Lyophilized from a 0.2 μm filtered solution of 20mM HAc-NaAc, 150mM NaCl, pH 4.0. |
Applications: | Applications:SDS-PAGE; WB; ELISA; IP. |
Storage: | Avoid repeated freeze/thaw cycles. Store at 2-8 oC for one month. Aliquot and store at -80 oC for 12 months. |
UOM: | 100ug/50ug/200ug/1mg/1g |
Source | E.coli |
Description | Recombinant Human Interleukin-2 is produced by our E.coli expression system and the target gene encoding Pro22-Thr153 is expressed. |
Names | Interleukin-2, IL-2, T-Cell Growth Factor, TCGF, Aldesleukin, IL2 |
Accession # | P60568 |
Formulation | Lyophilized from a 0.2 μm filtered solution of 20mM HAc-NaAc, 150mM NaCl, pH 4.0. |
Shipping |
The product is shipped at ambient temperature. |
Reconstitution |
Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100 μg/ml. Dissolve the lyophilized protein in ddH2O. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
Storage |
Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 4-7°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months. |
Biological Activity |
ED50 is less than 0.1 ng/ml. Specific Activity of 1.0 x 10^7 IU/ mg. |
Purity |
Greater than 95% as determined by reducing SDS-PAGE. |
Endotoxin | Less than 0.1 ng/µg (1 IEU/µg) as determined by LAL test. |
Amino Acid Sequence |
MPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKP LEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIIS TLT
|
Background | Recombinant Human Interleukin-2 is a highly purified protein with a molecular weight of approximately 15,300 Daltons. The chemical name is des-alanyl-1, serine-125 Human Interleukin-2. It is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the Human IL-2 gene, and the resulting expression clone encodes a modified Human IL-2. This recombinant form differs from native Interleukin-2 in following ways: 1) it is not glycosylated; 2) the molecule has no N-terminal alanine; 3) the molecule has serine substituted for cysteine at amino acid position 125; 4) the aggregation state of molecule is likely to be different from that of native IL-2. |